United States Orphan Drugs Market to Reach USD 486.51 Billion by 2032 | CAGR 9.1% | Biologics & Gene Therapies Drive Growth | Key Players: Johnson & Johnson, Vertex, AbbVie, Novartis, Pfizer

Orphan Drugs Market Size

The global orphan drugs market reached US$ 223.76 billion in 2023 and is projected to grow to US$ 486.51 billion by 2032, expanding at a CAGR of 9.1% during the forecast period from 2024 to 2032. Orphan drugs are medications indicated to treat, prevent, or diagnose rare diseases. According to the U.S. Food and Drug Administration (FDA), an orphan disease is defined as a condition affecting fewer than 200,000 patients in the country. The European Medicines Agency (EMA) defines a rare disease as one affecting fewer than 5 in 10,000 people across the European Union. The World Health Organization (WHO) classifies orphan diseases as those impacting fewer than 65 individuals per 100,000 population.

Orphan designation is a legal procedure, as per Orphanet, which allows medicinal substances with potential therapeutic benefit for rare diseases to be formally recognized before their first human administration or during clinical development. Despite their critical role, developing orphan drugs is less financially attractive for pharmaceutical companies due to limited patient populations and smaller market potential. To incentivize development, governments and regulatory authorities worldwide provide benefits such as tax credits, market exclusivity, and expedited regulatory approvals, encouraging pharmaceutical firms to invest in these novel therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/orphan-drugs-market?Juli

Recent Developments:

✅ October 2025: BioMarin Pharmaceutical received FDA approval for a next-generation gene therapy targeting a rare metabolic disorder, expanding its orphan drug portfolio.

✅ September 2025: Vertex Pharmaceuticals launched a new orphan drug for cystic fibrosis with enhanced efficacy, improving patient outcomes and reducing treatment burden.

✅ August 2025: Sarepta Therapeutics announced the commercial launch of an advanced exon-skipping therapy for Duchenne muscular dystrophy in Europe, following regulatory clearance.

✅ June 2025: Regeneron Pharmaceuticals expanded its rare disease pipeline with a biologic therapy targeting a previously untreated genetic condition, supported by accelerated regulatory review.

✅ March 2025: Novartis launched an AI-driven patient identification platform to optimize clinical trial recruitment for orphan drug studies, improving trial efficiency and enrollment rates.

✅ October 2024: Can-Fite BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for Namodenoson, indicated for the treatment of pancreatic cancer.

✅ April 2024: The European Commission granted orphan medicinal product designation for Zatolmilast, developed by Shionogi & Co., Ltd. Zatolmilast is an investigational drug for the treatment of Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.

Mergers & Acquisitions:

✅ November 2025: Vertex Pharmaceuticals acquired a small biotech specializing in RNA-based therapies for rare diseases to strengthen its orphan drug pipeline.

✅ September 2025: BioMarin Pharmaceutical partnered with a gene therapy developer to co-develop treatments for ultra-rare metabolic disorders.

✅ June 2025: Sarepta Therapeutics acquired a European clinical-stage biotech focused on neuromuscular orphan diseases to expand its research and development capabilities.

Key Players:
STERIS | Getinge | Narang Medical Limited | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Stryker | SKYTRON, LLC | Baxter | ALVO Medical Sp. z o.o. | Mizuho OSI | SternMed GmbH

Key Players:
Johnson & Johnson Services, Inc. | AbbVie Inc. | Vertex Pharmaceuticals Incorporated | AstraZeneca | Incyte | Biogen | Novartis AG | F. Hoffmann-La Roche Ltd | Pfizer Inc. | Bristol-Myers Squibb Company

Key Highlights:

• Johnson & Johnson Services, Inc. - Holds a 14.5% share, with a strong portfolio of orphan drugs for genetic and metabolic disorders and global distribution capabilities.

• AbbVie Inc. - Holds a 12.8% share, specializing in rare hematologic, immunologic, and neurological orphan therapies.

• Vertex Pharmaceuticals Incorporated - Holds a 13.2% share, a leader in cystic fibrosis and advanced gene- and RNA-based orphan drug development.

• AstraZeneca - Holds a 10.1% share, focusing on rare oncology and metabolic diseases through biologics and small-molecule therapies.

• Incyte - Holds a 6.4% share, concentrating on rare cancers and hematologic disorders via targeted therapies.

• Biogen - Holds a 7.1% share, with neurology-focused orphan drugs including treatments for spinal muscular atrophy.

• Novartis AG - Holds a 11.3% share, offering gene therapies, enzyme replacement therapies, and other orphan drugs for rare genetic disorders.

• F. Hoffmann-La Roche Ltd - Holds a 9.2% share, providing biologics, gene therapies, and personalized treatments for oncology and metabolic disorders.

• Pfizer Inc. - Holds a 10.0% share, developing orphan drugs across oncology, rare hematologic, and genetic conditions.

• Bristol-Myers Squibb Company - Holds a 5.4% share, focused on rare hematologic and immunologic diseases, with an expanding orphan drug pipeline.

Buy Now & Unlock 360° Market Intelligence:- https://www.datamintelligence.com/buy-now-page?report=orphan-drugs-market?Juli

Market Segmentation:

➥By Product Type, Small Molecule Drugs dominate the market with a 38% share, driven by their established use in treating rare metabolic, hematologic, and genetic disorders. Biologic Drugs account for 52% of the market, comprising Gene Therapies, Monoclonal Antibodies, and Other Biologics, reflecting growing adoption of advanced therapies for rare and ultra-rare diseases. Gene Therapies represent 20%, Monoclonal Antibodies hold 18%, and Other Biologics contribute 14%. The Others segment, including supportive therapies and combination products, accounts for 10%.

➥By Therapy Area, Oncology leads with a 28% share, driven by the increasing prevalence of rare cancers and targeted therapies. Hematology Diseases account for 18%, including orphan drugs for rare blood disorders like hemophilia. Central Nervous System (CNS) therapies represent 12%, covering conditions such as spinal muscular atrophy and rare neurological disorders. Cardiovascular and Endocrine orphan drugs hold 8% and 7%, respectively, addressing rare heart conditions and metabolic disorders. Respiratory conditions account for 5%, Immunologic Conditions 6%, Gastro-Intestinal 4%, Musculoskeletal 4%, and Dermatology 3%.

Regional Insights:

North America dominates the global orphan drugs market with an estimated 42% share, driven by the presence of leading pharmaceutical companies, strong healthcare infrastructure, high R&D investments, and supportive government policies including the Orphan Drug Act in the U.S. Europe holds around 28% of the market, supported by well-established healthcare systems, regulatory incentives for rare disease therapies, and growing adoption of advanced biologics across countries like Germany, France, and the U.K.

The Asia-Pacific region is witnessing the fastest growth, accounting for approximately 18%, fueled by increasing healthcare investments, rising rare disease awareness, expanding clinical trials, and the growing presence of multinational pharmaceutical companies in countries such as China, India, and Japan. Latin America contributes about 7%, driven by improving healthcare infrastructure and rising government initiatives for rare disease treatment in Brazil and Mexico. The Middle East & Africa region holds the remaining 5%, supported by growing awareness of rare diseases, increasing healthcare facilities, and regional incentives for orphan drug adoption.

Speak to Our Analyst and Get Customization in the report as per your requirements:- https://www.datamintelligence.com/customize/orphan-drugs-market?JUli

Market Dynamics:

Drivers: The orphan drugs market is primarily driven by the rising prevalence of rare diseases globally and the growing need for effective therapies for conditions with limited or no treatment options. Government incentives, such as tax credits, market exclusivity, and expedited regulatory approvals, encourage pharmaceutical companies to invest in orphan drug development. Increasing R&D investments by leading pharmaceutical firms, coupled with advances in gene therapies, biologics, and precision medicine, are further boosting market growth.

Restraints: Despite growth opportunities, the market faces challenges due to the high cost of orphan drugs, which limits patient access and healthcare reimbursement. The small patient populations for rare diseases can make development less financially attractive, and stringent regulatory requirements may slow drug approvals and commercialization.

Opportunities: There is significant potential in emerging markets, where increasing healthcare investments, improving rare disease awareness, and expanding healthcare infrastructure are driving adoption of orphan drugs. The development of advanced biologics, gene therapies, and personalized medicines presents opportunities for addressing unmet needs in rare diseases. Strategic partnerships, collaborations, and licensing agreements between biotechnology and pharmaceutical companies also offer avenues for market expansion.

Trends: Key trends in the orphan drugs market include the shift from small molecules to biologics, the growing use of gene and cell therapies, and the adoption of AI and digital tools for patient identification, clinical trial recruitment, and drug development. Companies are increasingly focusing on targeted therapies and precision medicine, aiming to improve efficacy, reduce side effects, and address previously untreatable rare diseases.

Emerging Players:

• The orphan drugs market is witnessing growth from several emerging players focusing on innovative therapies for rare diseases. Key emerging companies include:

• Can-Fite BioPharma Ltd. - Developing novel therapies for rare cancers and inflammatory disorders, with orphan drug designations granted for multiple pipeline candidates.

• Mustang Bio - Focused on gene and cell therapies for rare genetic and hematologic diseases, leveraging advanced biotechnology platforms.

• Kind Pharmaceuticals LLC - Specializes in targeted therapies for ultra-rare conditions, including genetic and metabolic disorders.

• Cabaletta Bio, Inc. - Developing T cell receptor-based therapies for rare autoimmune and genetic diseases, aiming to expand treatment options for underserved patient populations.

• Ionis Pharmaceuticals, Inc. - Leader in RNA-targeted therapies, developing multiple orphan drugs for rare neurological, cardiovascular, and metabolic disorders.

• These emerging players are driving innovation in the orphan drugs space by introducing advanced biologics, gene therapies, and precision medicine approaches, complementing the portfolios of established pharmaceutical companies.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.